• Polyrizon completed enrollment and randomization of 120 participants across five U.S. sites in its clinical study of NASARIX, an investigational nasal hydrogel.
• The randomized, controlled trial compares NASARIX with saline in adults with allergic rhinitis; 144 individuals were screened to reach enrollment.
• NASARIX forms a protective barrier within the nasal cavity designed to limit allergen contact with the nasal mucosa.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Polyrizon Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610270816PRIMZONEFULLFEED9853909) on October 27, 2026, and is solely responsible for the information contained therein.